Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
R1 RCM Inc (RCM) Insider Trading Activity
Healthcare • Health Information Services • 29,400 employees
R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance. R1 RCM Inc. was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. The company was incorporated in 2003 and is headquartered in Murray, Utah.
Total Value
-$535,466,385.24
Total Shares
-35,248,275
Average Trade Value
-$21,418,655.41
Most Active Insider
Tcp Asc Achi Series Lllp
Total Activity: $436,292,077
Largest Single Transaction
$436,292,077
by Tcp Asc Achi Series Lllp on Nov 19, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Nov 19, 2024 | 62,453 | $893,078 | 0 | Sale to Issuer | ||
Principal Accounting Officer
|
Nov 19, 2024 | 6,767 | $0 | 33,522 (+20.2%) | Grant | |
Principal Accounting Officer
|
Nov 19, 2024 | 33,522 | $479,365 | 0 | Sale to Issuer | |
Nov 19, 2024 | 22,241 | $318,046 | 0 | Sale to Issuer | ||
Chief Commercial Officer
|
Nov 19, 2024 | 306,621 | $0 | 356,975 (+85.9%) | Grant | |
Director, 10% Owner
|
Nov 19, 2024 | 30,548,388 | $436,292,077 | 154,837,588 (-19.7%) | Sale | |
Nov 19, 2024 | 61,041 | $872,886 | 0 | Sale to Issuer | ||
Nov 19, 2024 | 98,238 | $0 | 3,485,379 (+2.8%) | Grant | ||
Nov 19, 2024 | 33,014 | $472,100 | 0 | Sale to Issuer | ||
Nov 19, 2024 | 3,485,379 | $49,840,920 | 0 | Sale to Issuer | ||
Chief Financial Officer
|
Nov 19, 2024 | 355,006 | $0 | 423,479 (+83.8%) | Grant | |
Chief Financial Officer
|
Nov 19, 2024 | 423,479 | $6,055,750 | 0 | Sale to Issuer | |
Nov 19, 2024 | 26,975 | $385,743 | 0 | Sale to Issuer | ||
President
|
Nov 19, 2024 | 332,323 | $0 | 640,191 (+51.9%) | Grant | |
President
|
Nov 19, 2024 | 640,191 | $9,154,731 | 0 | Sale to Issuer | |
Nov 19, 2024 | 26,975 | $385,743 | 0 | Sale to Issuer | ||
Nov 19, 2024 | 87,765 | $1,255,040 | 0 | Sale to Issuer | ||
Chief Executive Officer
|
Nov 19, 2024 | 1,247,137 | $0 | 1,604,819 (+77.7%) | Grant | |
Chief Executive Officer
|
Nov 19, 2024 | 1,604,819 | $22,948,912 | 0 | Sale to Issuer | |
Nov 19, 2024 | 49,522 | $708,165 | 0 | Sale to Issuer | ||
Chief Commercial Officer
|
Nov 19, 2024 | 356,975 | $5,104,743 | 0 | Sale to Issuer | |
Nov 19, 2024 | 53,748 | $0 | 22,241 (-241.7%) | Sale to Issuer | ||
Nov 19, 2024 | 56,962 | $0 | 20,954 (-271.8%) | Sale to Issuer | ||
Nov 19, 2024 | 20,594 | $294,494 | 0 | Sale to Issuer | ||
Principal Accounting Officer
Officer
|
Oct 1, 2024 | 324 | $4,594 | 26,755 (-1.2%) | Payment of Exercise Price |